Functional role of the MUC1-C oncoprotein in non-small cell lung cancer

MUC1-C 癌蛋白在非小细胞肺癌中的功能作用

基本信息

  • 批准号:
    8634063
  • 负责人:
  • 金额:
    $ 51.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2017-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Non-small cell lung cancers (NSCLCs), particularly those harboring certain EGFR or K-RAS mutations, are often unresponsive to molecularly targeted agents and have a poor prognosis. Mucin 1 (MUC1) is a transmembrane glycoprotein that is overexpressed in most NSCLCs. However, it is not known if MUC1 is of importance to NSCLC cell growth and survival. In this regard, there are no available genetically-engineered mouse models to study MUC1 involvement in NSCLC initiation, progression or maintenance. MUC1 consists of two subunits~ an N-terminal extracellular mucin subunit (MUC1-N) and a C- terminal oncogenic transmembrane subunit (MUC1-C). The MUC1-C cytoplasmic domain functions as a substrate for EGFR and MET, and interacts with effectors, such as PI3K, that have been linked to NSCLC development. Overexpression of MUC1-C induces transformation and associated gene signatures that are predictive of decreased disease-free and overall survival in NSCLC patients. Moreover, inhibition of the MUC1-C subunit in NSCLC cells is associated with downregulation of the PI3K->AKT pathway and loss of survival. The overall objective of the proposed work is to define the functional role of MUC1-C in NSCLC. Our hypothesis is that MUC1-C contributes to the pathogenesis of NSCLC and that MUC1-C function is essential for survival of NSCLC cells with EGFR and K-RAS mutations. The proposed work will address this hypothesis in a new MUC1-C-driven mouse model of NSCLC and through the use of recently developed MUC1-C inhibitors. The theoretical concept that MUC1-C is a target for the treatment of NSCLC is novel and could shift current research and clinical paradigms. The Specific Aims are: (1) To define involvement of MUC1-C in development of NSCLC in mouse models~ (2) To assess the role of MUC1-C in NSCLC with EGFR mutations~ (3) To determine whether MUC1-C is of importance to development of K-RAS mutant NSCLC~ and (4) To identify how MUC1-C contributes to NSCLC cell survival.
描述(由申请人提供):非小细胞肺癌(NSCLC),特别是携带某些EGFR或K-RAS突变的NSCLC,通常对分子靶向药物无反应,预后不良。 粘蛋白1(MUC 1)是一种跨膜糖蛋白,在大多数NSCLC中过表达。 然而,目前尚不清楚MUC 1是否对NSCLC细胞的生长和存活具有重要意义。 在这方面,没有可用的基因工程小鼠模型来研究MUC 1参与NSCLC的发生、进展或维持。 MUC 1由两个亚基组成--N末端细胞外粘蛋白亚基(MUC 1-N)和C末端致癌跨膜亚基(MUC 1-C)。 MUC 1-C胞质结构域作为EGFR和MET的底物发挥作用,并与与NSCLC发展相关的效应物(如PI 3 K)相互作用。 MUC 1-C过表达诱导转化和相关基因特征,可预测NSCLC患者的无病生存期和总生存期降低。 此外,NSCLC细胞中MUC 1-C亚基的抑制与PI 3 K->AKT途径的下调和存活率的丧失相关。 拟议工作的总体目标是确定MUC 1-C在NSCLC中的功能作用。 我们的假设是MUC 1-C有助于NSCLC的发病机制,并且MUC 1-C功能对于EGFR和K-RAS突变的NSCLC细胞的存活至关重要。 拟议的工作将在新的MUC 1-C驱动的NSCLC小鼠模型中并通过使用最近开发的MUC 1-C抑制剂来解决这一假设。 MUC 1-C作为NSCLC治疗靶点的理论概念是新颖的,可能会改变当前的研究和临床模式。 具体目标是:(1)在小鼠模型中明确MUC 1-C在NSCLC发生发展中的作用;(2)评估MUC 1-C在EGFR突变的NSCLC中的作用;(3)确定MUC 1-C是否在K-RAS突变的NSCLC发生发展中起重要作用;(4)确定MUC 1-C如何促进NSCLC细胞存活。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DONALD W. KUFE其他文献

DONALD W. KUFE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DONALD W. KUFE', 18)}}的其他基金

Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer
使用抗体药物偶联物靶向 MUC1-C 治疗晚期前列腺癌
  • 批准号:
    10512804
  • 财政年份:
    2022
  • 资助金额:
    $ 51.82万
  • 项目类别:
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression
靶向 MUC1-C 治疗小细胞肺癌进展
  • 批准号:
    10354347
  • 财政年份:
    2022
  • 资助金额:
    $ 51.82万
  • 项目类别:
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression
靶向 MUC1-C 治疗小细胞肺癌进展
  • 批准号:
    10563188
  • 财政年份:
    2022
  • 资助金额:
    $ 51.82万
  • 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
  • 批准号:
    10004595
  • 财政年份:
    2018
  • 资助金额:
    $ 51.82万
  • 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
  • 批准号:
    9789217
  • 财政年份:
    2018
  • 资助金额:
    $ 51.82万
  • 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
  • 批准号:
    10478059
  • 财政年份:
    2018
  • 资助金额:
    $ 51.82万
  • 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
  • 批准号:
    10224740
  • 财政年份:
    2018
  • 资助金额:
    $ 51.82万
  • 项目类别:
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
MUC1-C 癌蛋白在非小细胞肺癌中逃避免疫破坏
  • 批准号:
    9913473
  • 财政年份:
    2012
  • 资助金额:
    $ 51.82万
  • 项目类别:
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
MUC1-C 癌蛋白在非小细胞肺癌中逃避免疫破坏
  • 批准号:
    9238148
  • 财政年份:
    2012
  • 资助金额:
    $ 51.82万
  • 项目类别:
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer
MUC1-C 癌蛋白在非小细胞肺癌中的功能作用
  • 批准号:
    8837576
  • 财政年份:
    2012
  • 资助金额:
    $ 51.82万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.82万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了